{'fraction_non_alphanumeric': 0.0426497277676951, 'fraction_numerical': 0.05353901996370236, 'mean_word_length': 5.450292397660819, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In vitro Activity of Moxifloxacin(BAY 12-8039) against Respiratory Tract Pathogens from Six Latin-American Countries

The in vitro antibacterial activity of moxifloxacin (BAY 12-8039) was evaluated against 636 isolates of respiratory tract pathogens. The isolates were collected from July 1997 to August 1998 in the frame of a multinational Latin American study. E-test strips calibrated to read moxifloxacin MIC ranges from 0.002 to 32 μg/ml were used in susceptibility testing. Weekly quality control tests in each laboratory ensured reproducibility. Laboratories from Argentina, Brazil, Chile, Colombia, Mexico and Uruguay participated. MIC90 for moxifloxacin were as follows: Streptococcus pneumoniae (304 isolates) 0.25 μg/ml, Haemophilus influenzae (135 isolates) 0.125 μg/ ml, Streptococcus pyogenes (66 isolates) 0.25 μg/ml, Moraxella catarrhalis (62 isolates) 0.25 μg/ml and methicillin-sensitive Staphylococcus aureus (69 isolates) 0.25 μg/ml. These results agreed with reports from other areas. Moxifloxacin showed excellent activity against respiratory pathogens from participant countries.